Determination of Plasma ET-1 by RIA - Risks and Limitations

S. M. Baumgartner-Parzer; P. Nowotny; O. Wagner; W. Waldhäusl

doi:10.1055/s-2007-978948

RSS-Feed abonnieren

Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.

https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000025.xml

Teilen / Bookmarken

Facebook Linkedin Weibo

PDF herunterladen

Horm Metab Res 1998; 30(10): 633-635
DOI: 10.1055/s-2007-978948

Originals Clinical

Determination of Plasma ET-1 by RIA - Risks and Limitations

S. M. Baumgartner-Parzer¹ , P. Nowotny¹ , O. Wagner² , W. Waldhäusl¹

¹Department of Internal Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Austria
²Institute of Clinical Chemistry and Pathobiochemistry, University of Leipzig, Germany

Weitere Informationen

Publikationsverlauf

1998

1998

Publikationsdatum:
20. April 2007 (online)

Auch verfügbar auf

als PDF herunterladen Lizenzen und Reprints

Plasma concentrations of the vasoconstrictor peptide endothelin-1 (ET-1) were determined in nonobese healthy subjects as well as in unspecified patients using three different commercially available radioimmunoassays (RIAs) and the respective recommended prepurification procedures. Depending on the antibody and extraction procedure applied different ET-1 concentrations were measured in identical plasma samples. Thus, this study clearly documents that ET-1 concentrations measured in plasma samples represent apparent concentrations which have to be interpreted with caution.

Key words

Endothelin-1 - Plasma Concentration - Radioimmunoassay - Quality Control